Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.
Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.
The study enrolled 35 patients, 34 of which were evaluable for response, says Liu.
In order to be eligible for the study, patients had to have had at least 1 prior platinum-based chemotherapy regimen. Patients in the study had received a median of 3 prior lines of therapy.
Among these 34 patients, the overall response rate was 29.4% (95% CI, 15.1-47.5), says Liu. Additionally, the median progression-free survival was 6.1 months, and the median duration of response was 9.0 months.
Regarding safety, the adverse effects (AEs) were consistent with previously reported data with adavosertib in this patient population, explains Liu. Common grade 3 or higher AEs included neutropenia, anemia, and fatigue.
Additionally, 2 patients discontinued treatment due to AEs; however, dose modifications and dose adjustments allowed the regimen to be well tolerated by most women, concludes Liu.